FDA approves Illumigene HSV 1&2 diagnostics for herpes simplex- Meridian Bioscience
Meridian Bioscience has received FDA clearance for two new molecular assays for the detection of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its Illumigene molecular platform. The Illumigene HSV 1&2 assays, launched in May this year in Europe, are now available in the US – they are the eighth and ninth assays added to the illumigene molecular menu now that includes C. difficile, Group A Streptococcus, Group B Streptococcus, Mycoplasma, Pertussis, Chlamydia and Gonorrhea.
Illumigene HSV 1&2 assays utilize loop-mediated isothermal DNA amplification (LAMP) technology for the qualitative detection and differentiation of HSV-1 and HSV-2 in cutaneous and mucocutaneous specimens. The test procedure is simple, sensitive and provides results in less than one hour.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins